Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 9Biliary Tract Neoplasms 5Stomach Neoplasms 4Cholangiocarcinoma 4Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Thyroid Carcinoma, Anaplastic 1Sarcoma 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroendocrine Tumors 1Locally Advanced Pancreatic Cancer 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Appendiceal Neoplasms 1Advanced Pancreatic Cancer 1Advanced Biliary Tract Cancer 1

Interventions

Gemcitabine 4lenvatinib 3durvalumab 3Cisplatin 3tislelizumab 2sintilimab 2pembrolizumab 2toripalimab 1titanium silicide 1theasinensin A 1surufatinib 1sitravatinib 1regorafenib 1S 1 (combination) 1Nivolumab 1Injections 1Folfox protocol 1Fluorouracil 1Cryosurgery 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Biliary Tract Cancer × surufatinib × Gastrointestinal × Clear all
NCT06708858 2024-11-27

Phase â…¡ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡